Antipsychotic therapy during early and late pregnancy. a systematic review

Schizophrenia Bulletin

Volumn 36, Issue 3, 2010, Pages 518-544

  Gentile, Salvatore ^a  

^a Mental Health Center N4   (Italy)

Author keywords

Antipsychotics; Gestational metabolic complications; Neonatal complications; Neuroleptics; Pregnancy; Safety

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BUTYROPHENONE DERIVATIVE; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; DIPHENYLBUTYLPIPERIDINE DERIVATIVE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PENFLURIDOL; PHENMETRAZINE; PHENOTHIAZINE DERIVATIVE; PIMOZIDE; PROCHLORPERAZINE; PROMETHAZINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SERTINDOLE; THIETHYLPERAZINE; THIORIDAZINE; THIOXANTHENE DERIVATIVE; TRIFLUOPERAZINE; UNINDEXED DRUG; ZIPRASIDONE; ZUCLOPENTHIXOL;

ACCESSORY SPLEEN; ACHONDROPLASIA; AKINESIA; ALBINISM; ANENCEPHALUS; ANKYLOBLEPHARON; ANUS ATRESIA; ASPLENIA; ATRESIA; BIPOLAR DISORDER; BIRTH DEFECT; BIRTH INJURY; BRAIN AQUEDUCT STENOSIS; BRAIN CYST; BRAIN MALFORMATION; CARDIOTOXICITY; CHILD DEATH; CHONDROMA; CLEFT LIP; CLEFT PALATE; CLUBFOOT; COLON MALFORMATION; CONGENITAL BLOOD VESSEL MALFORMATION; CONGENITAL CATARACT; CONGENITAL HEART BLOCK; CONGENITAL HEART DISEASE; CONGENITAL HEART MALFORMATION; CONGENITAL MALFORMATION; CONGESTIVE CARDIOMYOPATHY; CONVULSION; CRANIOFACIAL SYNOSTOSIS; CRYPTORCHISM; CYANOSIS; CYSTIC LYMPHANGIOMA; DIGESTIVE SYSTEM MALFORMATION; DOWN SYNDROME; DRUG MEGADOSE; DRUG SAFETY; EAR MALFORMATION; ENCEPHALOCELE; ENDOCARDIAL FIBROELASTOSIS; ESOPHAGUS ATRESIA; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FACE EDEMA; FACE MALFORMATION; FALLOT TETRALOGY; FEEDING DISORDER; FETUS DEATH; FETUS HEART RATE; FETUS MALFORMATION; FEVER; FINGER MALFORMATION; FIRST TRIMESTER PREGNANCY; FLATFOOT; GASTROESOPHAGEAL REFLUX; GASTROSCHISIS; GENITAL MALFORMATION; GREAT VESSELS TRANSPOSITION; GROWTH RETARDATION; HEARING IMPAIRMENT; HEART ARRHYTHMIA; HEART ATRIUM SEPTUM DEFECT; HEART BLOCK; HEART FAILURE; HEART VENTRICLE SEPTUM DEFECT; HIP DYSPLASIA; HUMAN; HYDROCELE; HYDROCEPHALUS; HYDRONEPHROSIS; HYPERBILIRUBINEMIA; HYPEREKPLEXIA; HYPERPROLACTINEMIA; HYPERREFLEXIA; HYPERTENSION; HYPOSPADIAS; HYPOTHERMIA; INFANTILE HYPOTONIA; INTESTINE MALFORMATION; INTESTINE OBSTRUCTION; INTRAUTERINE GROWTH RETARDATION; IRRITABILITY; JAUNDICE; KIDNEY DYSPLASIA; KIDNEY MALFORMATION; LIMB DEFORMITY; LIMB MALFORMATION; LOW DRUG DOSE; LUNG EMPHYSEMA; LUNG TOXICITY; MATERNAL CARE; MENINGOCELE; MENINGOMYELOCELE; MENTAL DEFICIENCY; MICROCEPHALY; MICROGNATHIA; MICROPHTHALMIA; MOTOR DYSFUNCTION; MOYAMOYA DISEASE; MULTIPLE MALFORMATION SYNDROME; MUSCLE HYPERTONIA; MUSCLE HYPOTONIA; MUSCLE MALFORMATION; NECROTIZING ENTEROCOLITIS; NEONATAL HYPOXEMIC ENCEPHALOPATHY; NEUROLOGIC DISEASE; NEUROMUSCULAR DISEASE; NEWBORN DISEASE; NEWBORN HYPOXIA; OMPHALOCELE; OPISTHOTONUS; PALATE MALFORMATION; PATENT DUCTUS ARTERIOSUS; PATENT FORAMEN OVALE; PERINATAL DEATH; PERINATAL MORBIDITY; PES EQUINOVARUS; PHARYNX DISEASE; PHOCOMELIA; PIERRE ROBIN SYNDROME; POLYDACTYLY; PRACTICE GUIDELINE; PREGNANCY COMPLICATION; PREGNANCY DIABETES MELLITUS; PREMATURE LABOR; PREMATURITY; PRIORITY JOURNAL; PSYCHOSIS; PYLORUS STENOSIS; RESPIRATORY DISTRESS; RESPIRATORY TRACT DISEASE; REVIEW; SEIZURE; SIDE EFFECT; SITUS INVERSUS; SKELETON MALFORMATION; SMALL FOR DATE INFANT; SPINA BIFIDA; SPONTANEOUS ABORTION; STILLBIRTH; SUBDURAL HEMATOMA; SYNDACTYLY; SYSTEMATIC REVIEW; TACHYCARDIA; TERATOGENICITY; TESTICLE ATRESIA; THANATOPHORIC DWARFISM; THERMOREGULATION; THIRD TRIMESTER PREGNANCY; TONGUE DISEASE; TORTICOLLIS; TRACHEOMALACIA; TREMOR; URINARY TRACT MALFORMATION; VARUS KNEE; VESICOURETERAL REFLUX; WITHDRAWAL SYNDROME;

ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, THIRD; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 77953185495     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbn107     Document Type: Review

References (209)

1. Odegard O. Fertility of psychiatric first admission in Norway 1936-1975. Acta Psychiatr Scand. 1980;62:212-220.
2. Miller WH, Bloom JD, Resnick MP. Prenatal care for pregnant chronic mental ill patients. Hosp Community Psychiatry. 1992;43:942-943.
3. Castle DJ, McGrath J, Kulkarni J. Reproductive, precon-ceptual and antenatal needs of women with schizophrenia. Women and Schizophrenia. Cambridge, UK: Cambridge University Press; 2000.
4. Coverdale JH, Bayer TL, McCullough LB, Chervenak FA. Respecting the autonomy of chronic mentally ill women in decision about contraception. Hosp Community Psychiatry. 1993;44:671-674.
5. Miller LJ, Finnrerty M. Sexuality, pregnancy, and child-bearing among women with schizophrenia-spectrum disorders. Hosp Community Psychiatry. 1996;47:502-506.
6. Gentile S. Special care-needs for schizoaffective women in childbearing age [abstract]. Turk J Psychiatry. 2006; 2(suppl 1):271.
7. McNeil TF, Kaij L, Malmquiat-Larsson A. Women with nonorganic psychosis: pregnancy's effect on mental health during pregnancy. Obstetric complications in schizophrenic patients. Acta Psychiatr Scand. 1984;70:140-148.
8. Coverdale JH, Turbort SH, Roberts H. Family planning needs and STD risk behaviours of female psychiatric outpatients. Br J Psychiatry. 1997;171:69-72.
9. Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and postpartum period. Am J Psychiatry. 2004;161:608-620.
10. Freeman MP, Gelenberg AJ. Bipolar disorder in women: reproductive events and treatment considerations. Acta Psychiatr Scand. 2005;112:88-96.
11. Swann AC. Special needs of women with bipolar disorder. Intellyst™ Medical Communication. International Congress on Women's Mental Health; 17-20 March 2004; Washington, DC. pp 4-18.
12. Burt VK, Rasgon N. Special considerations in treating bipolar disorder in women. Bipolar Disord. 2004;6:2-13.
13. Grof P. Protective effect of pregnancy with lithium-responsive bipolar disorder. J Affect Disord. 2000;61:31-39.
14. Kendell RE, Chalmers JC, Plaz C. Epidemiology of puerperal psychosis. Br J Psychiatry. 1987;150:622-673.
15. Pugh TF, Jerath BK, Schmidt WM, Reed RB. Rates of mental disease related to childbearing. N Engl J Med. 1963;268:1224-1228.
16. Terp IM, Mortensen PB. Postpartum psychosis: clinical diagnosis and relative risk of admission after parturition. Br J Psychiatry. 1998;172:521-526.
17. Freeman M, Smith K, Freeman S, et al. The impact of reproductive events on the course of bipolar disorder in women. J Clin Psychiatry. 2002;63:284-287.
18. Gentile S. Atypical antipsychotics in the treatment of bipolar disorder. More shadows than lights. CNS Drugs. 2007;21:367-387.
19. Gentile S. The clinical utilization of atypical antipsychotics in pregnancy and lactation. Ann Pharmacother. 2004;38:1265-1271.
20. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rose-nheck RA, Perkins DD. for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:209-223.
21. Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry. 2002;63(suppl 4):42-55.
22. Trixler M, Gáti A, Fekete S, Tényi T. Use of antipsychotics in the management of schizophrenia during pregnancy. Drugs. 2005;65:1193-1206.
23. Nurnberg GH, Prudic J. Guidelines for treatment of psychosis during pregnancy. Hosp Community Psychiatry. 1984;35:67-71.
24. Collins JA, Fauser BCJM. Balancing the strengths of systematic and narrative reviews. Hum Reprod Update. 2005;11:103-104.
25. Altshuler L, Cohen L, Martin S, Burt VK, Gitlin M, Mintz J. Pharmacological management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry. 1996;153:592-596.
26. Starfield B. Quality of care-research: internal elegance and external relevance. JAMA. 1998;280:1006-1008.
27. Australian Drug Evaluation Committee (ADEC). ADEC Pregnancy Category. http://www.tga.gov.au/DOCS/HTLM/medpreg.htm. Accessed June 19, 2008.
28. Solian. Product information. http://www.sanofi-aventis.com. au/products/aus-pi-solian.pdf. Accessed June 19, 2008.
29. Product Information. Abilify (aripiprazole). Princeton, NJ: Bristol-Myers Squibb; 2003. Aripiprazole. Drugdex drug evaluations, 1974-2003. Thomson Micromedex, Healthcare Series Vol117.
30. Mendhekar DN, Sunder KR, Andrade C. Aripiprazole use in a pregnant schizoaffective woman. Bipolar Disord. 2006;8:299-300.
31. Mervak B, Collins J, Valenstein M. Case report of aripiprazole usage during pregnancy. Arch Womens Ment Health. [published online ahead of print June 26, 2008].
32. Mendhekar DN, Sharma JB, Srilakshmi P. Use of aripiprazole during late pregnancy in a woman with psychotic illness [letter]. Ann Pharmacother. 2006;40:575.
33. Clozaril. Prescribing information. http://www.pharma.us. novartis.com/product/pi/pdf/Clozaril.pdf. Accessed March 20, 2007.
34. Lieberman J, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. In: Lapierre Y, Jones B, eds. Clozapine in Treatment Resistant Schizophrenia: A Scientific Update. London, UK: Royal Society of Medicine; 1992.
35. Bazire S. Psychotropic Drug Directory. Salisbury, UK: Five-pin Limited; 2005:239.
36. Dev VJ, Krupp P. Adverse event profile and safety of cloza-pine. Rev Contemp Pharmacother. 1995;6:197-208.
37. Vavrusova L, Konikova M. Clozapine administration during pregnancy [in Czechoslovakian]. Ceska Slov Psychiatr. 1998;94:282-285.
38. Nguyen HN, Lalonde P. Clozapine and pregnancy [in French]. Encephale. 2003;29:119-124.
39. Dickson RA, Hogg L. Pregnancy of a patient treated with clozapine. Psychiatr Serv. 1998;49:1081-1083.
40. Waldman MD, Safferman A. Pregnancy and clozapine [letter]. Am J Psychiatry. 1993;150:168-169.
41. Mendhekar DN, Sharma JB, Srivastava PK, et al. Clozapine and pregnancy [letter]. J Clin Psychiatry. 2003;64:850.
42. Rzewuska M. Leczenie zaburzeá psychicznych (in Polish). Warszawa, Poland: PZWL; 2000.
43. Reis M, Källén B. Maternal use of antipsychotics in early pregnancy and delivery outcome. J Clin Psychopharmacol. 2008;28:279-288.
44. Karakula H, Szajer K, Spila B, Gryza A, Guy A, Przywara G. Clozapine and pregnancy. A case history. Pharmacopsy-chiatry. 2004;37:303-304.
45. Stoner SC, Sommi RW, Jr, Marken PA, Anya L, Vaughn J. Clozapine use in two full-term pregnancies [letter]. J Clin Psychiatry. 1997;58:364-365.
46. Di Michele V, Ramenghi LA, Sabatino G. Clozapine and lorazepam administration in pregnancy [letter]. Eur Psychiatry. 1996;11:214.
47. Yogev Y, Bem-Haroush A, Kaplan B. Maternal clozapine treatment and decreased fetal hearth rate variability. Int J Gynaecol Obstet. 2002;79:259-260.
48. Klys M, Rojek S, Rzepecka-Woźniak E. Neonatal death following clozapine self-poisoning in late pregnancy. An unusual case-report. Forensic Sci Int. 2007;171:e5-e10.
49. Barnas C, Bergant A,Hummer M, Saria A, Fleischhacker WW. Clozapine concentrations in maternal and fetal plasma, amniotic fluid, and breast milk [letter]. Am J Psychiatry. 1994;151:945.
50. Gupta N, Grover S. Safety of clozapine in 2 successive pregnancies [letter]. Can J Psychiatry. 2004;49:863.
51. Tényi T, Trixler M. Clozapine in the treatment of pregnant schizophrenic women [in Hungarian]. Psychiatr Danub. 1998;10:15-18.
52. Mendhekar DN. Possible delayed speech acquisition with clozapine therapy during pregnancy and lactation [letter]. J Neuropsychiatry Clin Neurosci. 2007;19:196-197.
53. Duran A, Ugur MM, Turan S, Emuk M. Clozapine use in two women with schizophrenia during pregnancy. J Psycho-pharmacol. 2008;22:111-113.
54. Zyprexa. Prescribing information http://pi.lilly.com/us/zypreza-pi.pdf. Accessed May 8, 2005.
55. Biswas PN, BR, Wilton LV, Pearce GL, Freehahtle S, Shakir SA. The pharmacovigilance of olanzapine: results of a post-marketing surveillance study on 8858 patients in England. J Psychopharmacol. 2001;15:265-271.
56. Goldstein DJ, Corbis LA, Fung MC. Olanzapine-exposed pregnancies and lactation: early experience. J Clin Psycho-pharmacol. 2000;20:399-403.
57. McKenna K, Koren G, Tetelbaum M. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry. 2005;66:444-449. (Pubitemid 40593572)
58. Arora M, Praharaj SK. Meningocele and ankyloblepharon following in utero exposure to olanzapine. Eur Psychiatry. 2006;21:341-346.
59. Spryropoulou AC, Zrvas IM, Soldatos CR. Hip dysplasia fol-lowingacaseofolanzapine exposed pregnancy:aquestionable association. Arch Womens Ment Health. 2006;9:219-222.
60. Yeshayahu Y. The use of olanzapine in pregnancy and congenital cardiac and musculoskeletal abnormalities [letter]. Am J Psychiatry. 2007;164:1759-1769.
61. Littrell KH, Johnson CG, Peabody BA, Hilligoss N. Anti-psychotics during pregnancy [letter]. Am J Psychiatry. 2000;157:1342.
62. Vemuri MP, Rasgon NL. A case of olanzapine-induced ges-tational diabetes mellitus in the absence of weight gain [letter]. J Clin Psychiatry. 2007;68:1989.
63. Aichhorn W, Yadzi K, Kralovec K, et al. Olanzapine plasma concentration in a newborn. J Psychopharmacol. [published online ahead of print February 28, 2008].
64. Friedman SH, Rosenthal MB. Treatment of perinatal delusional disorder: a case report. Int J Psychiatry Med. 2003;33:391-394.
65. Kirchheiner J, Berghöfer A, Bolk-Weischedel D. Healthy outcome under olanzapine treatment in a pregnant woman. Pharmacopsychiatry. 2000;33:78-80.
66. Newport J, Calamaras MR, DeVane CL, et al. Atypical an-tipsychotic administration during late pregnancy: placental passage and obstetrical outcome. Am J Psychiatry. 2007;164:1214-1220.
67. Nagy A, Tenyi T, Lenard K, Herold R, Wilhelm F, Trixler M. Olanzapine and pregnancy [in Hungarian]. Orv Hetil. 2001;142:137-138.
68. Neumann NU, Frasch K. Olanzapine and pregnancy [in German]. 2 case reports. Nevernatz. 2001;72:876-878.
69. Mendhekar DN, War L, Sharma JB, Jiloha RC. Olanzapine and pregnancy. Pharmacopsychiatry. 2002;35:122-123.
70. Malek-Ahmadi PM. Olanzapine in pregnancy [letter]. Ann Pharmacother. 2001;35:1294-1295.
71. Lim LM. Olanzapine and pregnancy. Aust N Z J Psychiatry. 2001;35:856-857.
72. Sharma V, Smith A, Mazmanian D. Olanzapine in the prevention of postpartum psychosis and mood episodes in bipolar disorder. Bipolar Disord. 2006;8:400-404.
73. Dervaux A, Ichou P, Pierrot F, Devianne F, Bavoux F. Olanzapine and pregnancy [abstract]. Eur Psychiatry. 2007;22:S110.
74. Kulkarni J, McCauley-Elsom K, Marston N, et al. Preliminary findings from the National Register of Antipsychotic Medication in Pregnancy. Aust N Z J Psychiatry. 2007;42: 38-44.
75. Klier CM, Mossaheb N, Saria A, Schloegelhofer M, Zernig G. Pharmacokinetics and elimination of quetiapine, venla-faxine, and trazodone during pregnancy and postpartum [letter]. J Clin Psychopharmacol. 2007;27:720-721.
76. Twaites BR, Wilton LV, Shakir SAW. The safety of quetiapine: results of a post-marketing surveillance study on 1728 patients in England. J Psychopharmacol. 2007;21: 392-399.
77. Balke LD. Quetiapine is effective in the treatment of bipolar affective disorder during pregnancy. Poster session presented at: 7th World Congress of Biological Psychiatry; July 1-6, 2001; Berlin, Germany.
78. Tényi T, Trixler M, Kerestes Z. Quetiapine and pregnancy [letter]. Am J Psychiatry. 2002;159:674.
79. Pace A, D'Agostino F. Quetiapine in pregnancy: a case report [in Italian]. Giorn It Ost Ginecol. 2003;XXV:381-385.
80. Taylor TM, O'Toole MS, Ohlsen RI, Walters J, Pilousley CS. Safety of quetiapine during pregnancy [letter]. Am J Psychiatry. 2003;160:588-589.
81. Lee A, Giesbrecht E, Dunn E, Ho S. Excretion of quetiapine in breast milk [letter]. Am J Psychiatry. 2004;161: 1715-1716.
82. Gentile S. Quetiapine-fluvoxamine combination during pregnancy and while breastfeeding [letter]. Arch Womens Ment Health. 2006;9:158-159.
83. Kruninger U, Meltzer V, Hiemke C, Herpich S. Pregnancy and lactation under treatment with quetiapine. Psychiatr Prax. 2007;34(suppl):75-76.
84. Cabuk D, Sayin A, Derinöz O, Biri A. Quetiapine use for the treatment of manic episode during pregnancy. Arch Womens Ment Health. 2007;10:235-236.
85. Risperdal (risperidone). Janssen, LP prescribing information.
86. Reilly T, Heylen SLE. Guidelines for the practical use of ris-peridone. In: Kane JM, Moller HJ, Awouters F, eds. Serotonin in Antipsychotic Treatment. New York, NY: Dekker Inc; 1996:357-368.
87. MacKay FJ, Wilton GL, Pearce SN, Freemantle SH, Mann RD. The safety of risperidone: a post-marketing study on 7684 patients. Hum Psychopharmacol Clin Exp. 1998;13:423-428.
88. Ratnayake T, Libretto SE. No complications with risperi-done treatment before and throughout pregnancy and during the nursing period [letter]. J Clin Psychiatry. 2002;63: 76-77.
89. Kato S, Sato J, Suzuki H. Anesthesia for caesarean section in a parturient taking risperidone and haloperidol. Masui. 2005;54:301-303.
90. Kim SW, Kim KM, Kim JM, et al. Use of long-acting inject-able risperidone before and throughout pregnancy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007; 31:543-545.
91. Dabbert D, Heinze M. Follow-up of a pregnancy with ris-peridone microspheres [letter]. Pharmacopsychiatry. 2006;39: 235.
92. Physician's Desk Reference. 55th ed. Montale, NJ: Medical Economics; 2001.
93. Grover S, Avasthi A. Risperidone in pregnancy: a case of oligohydramnios [in German]. J Psychiatry. 2004;7:56-57.
94. McCauley-Elsom K, Kulkarni J. Managing psychosis in pregnancy. Aust N Z J Psychiatry. 2007;41:289-292.
95. Coppola D, Russo LJ, Kwarta RF, Jr, Varughese S, Schmider J. Evaluating the postmarketing experience of ris-peridone use during pregnancy. Pregnancy and neonatal outcomes. Drug Saf. 2007;30:247-264
96. Sertindole.Supportive material. http://www.serdolect.com/supportive- material/Default.aspx. Accessed June 19, 2008.
97. Geodon.Warning and precautions. http://www.rxlist.com/cgi/generic/ ziprasidone-wcp.htm. Accessed April 30, 2007.
98. Seay PH, Field WE. Toxicological studies on haloperidol. Int J Neuropsychiatry. 1968;3(suppl):1-4.
99. Dieulangard P, Coignet J, Vical JC. Sur un cas d'ectro-phocomelia peut-être d'origine médicamenteuse [in French]. Bull Fed Soc Gynecol Obstet Lang Fr. 1966;18:85-87.
100. Kopelman AE, Mc Cullar FW, Heggeness L. Limb malformations following maternal use of haloperidol. JAMA. 1975;231:62-64
101. Council on drugs. Evaluation of a new antipsychotic agent. Haloperidol (Haldol). JAMA. 1968;205:105-106.
102. Godet PF, Marie-Cardine M. Neuroleptics, schizophrenia, and pregnancy. Epidemiological and teratologic study [in French]. Encéphale. 1991;7:543-547.
103. Hanson JW, Oakley GP. Haloperidol and limb deformity [letter]. JAMA. 1975;321:26.
104. Van Waes A, Van de Velde E. Safety evaluation of haloper-idol in the treatment of hyperemesis gravidarum. J Clin Pharmacol. 1969;9:224-227.
105. Diav-Citrin O, ShechtmanS, Ornoy S,et al. Safety ofhaloper-idol and penfluridol in pregnancy: a multicenter, prospective, controlled study. J Clin Psychiatry. 2005;66:317-322.
106. Sexson WR, Barak Y. Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy. J Peri-natol. 1989;9:170-172.
107. Mohan MS, Patole SK, Whitehall JS. Severe hypothermia in a neonate following antenatal exposure to haloperidol [letter]. J Paediatr Child Health. 2000;36:412.
108. O'Collins K, Comer JB. Maternal haloperidol therapy associated with dyskinesia in a newborn. Am J Health Syst Pharm. 2003;60:2253-2255.
109. Walloch JE, Klauwer C, Lanczik M, Brockington JE, Korn-huber J. Delusional denial of pregnancy as a special form of Cotard's Syndrome. Psychopathology. 2007;40:61-64.
110. Hansen LM, MegerianG, Donnenfeld AE. Haloperidol overdose during pregnancy. Obstet Gynecol. 1997;90:659-661.
111. Bjarnason NH, Rode L, Dalhoff K. Fetal exposure to pimo-zide: a case-report. J Reprod Med. 2006;51:443-444.
112. Szabo KT, Brent RL. Species differences in experimental teratogenesis by tranquillising agents [letter]. Lancet. 1974;1:565.
113. Favre-Tissot M, Broussolle P. Du pouvoir teratogene éven-tuel des produits psychopharmacologique. In: Brill A, ed. Neuropsychopharmacology. Proceedings of the Fifth International Congress of the Collegium Internationale Neuro-psy-chopharmacologicum. Amsterdam, The Netherlands: Excepta Medica Foundation; 1967:583-596.
114. Rawlings WJ, Ferguson R, Madison TG. Phenmetrazine and trifluoperazine [letter]. Med J Aust. 1963;1:370.
115. Milkovich L, van den Berg BJ. An evaluation of the terato-genicity of certain antinauseant drugs. Am J Obstet Gynecol. 1976;125:244-248.
116. Rumeau-Roquette C, Goujard J, Huel G. Possible terato-genic effect of phenotiazines in humans beings. Teratology. 1975;15:57-64.
117. Slone D, Siskind V, Heinonen OP, Monson RR, Kauffman DW, Shapiro S. Antenatal exposure to phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol. 1977;128:486-488.
118. Haxton MJ, Bell J. Fetal anatomical abnormalities and other associated factors in middle-trimester abortion and their relevance to patient counselling. Br J Obstet Gynaecol. 1983;90:501-506.
119. Royal College of Obstetricians and Gynaecologists. The investigation and treatment of couples with recurrent miscarriage. Guidelines No. 17. http://www.rcog.org.uk/resources/Public/pdf/Recurrent-Miscarriage-No17.pdf. Accessed June 22, 2008.
120. Scokel PW, Jones WN. Infant jaundice after phenothiazine drugs for labor: an enigma. Obstet Gynecol. 1962;20: 124-127.
121. Stika L, Elisova K, Honzáková H, et al. Effects of drug administration in pregnancy on children's school behaviour. Pharm Weekbl Sci. 1990;12:252-255.
122. Singh S, Padmanabhan R. Teratogenic effects of chlorprom-azine hydrochloride in rat fetuses. Indian J Med Res. 1978;67:300-309.
123. Hannah RS, Roth SH, Spira AW. The effects of chlorprom-azine and phenobarbital on cerebellar Purkinje cells. Teratology. 1982;26:21-25.
124. Kris BE, Carmichael DM. Chlorpromazine maintenance therapy during pregnancy and confinement. Psychiatr Q. 1957;31:690-695.
125. Ayd FJ, Jr. Children born to mothers treated with chlor-promazine during pregnancy. Clin Med. 1964;71:1758-1763.
126. Kris BE. Children of mothers maintained on pharmacother-apy during pregnancy and postpartum. Curr Ther Res. 1965;7:785-789
127. SobelDE. Fetal damage duetoECT, insulin coma, chlorprom-azine, or reserpine. Arch Gen Psychiatry. 1960;2:606-611.
128. O'Leary JL, O'Leary JA. Non-thalidomide ectromelia. Obstet Gynecol. 1964;23:17-20.
129. Falterman CG, Richardson CJ. Small left colon syndrome associated with maternal ingestion of psychotropic drugs. J Pediatr. 1980;97:308-310.
130. Ben-Amital D, Merlob P. Neonatal fever and cyanotic spells from maternal chlorpromazine [letter]. DICP. 1991;25:1009-1010.
131. Ergenkon E, Atalay Y, Tunaoglu S, Koc E. Transient heart block in a newborn due to maternal antipsychotic treatment during pregnancy. Eur J Pediatr. 2000;159:137-138.
132. Auerbach JG, Hans SL, Marcus J, Naeir S. Maternal psy-chotropic medication and neonatal behavior. Neurotoxicol Teratol. 1992;14:399-406.
133. Levy W, Wisniewski K. Chlorpromazine causing extrapyra-midal dysfunction in newborn infant of psychotic mother. N Y State J Med. 1974;74:684-685.
134. Nielsen HC, Wiriyathian S, Rosenfeld CR, Levenko K, Garriott JC. Chlorpromazine excretionby the neonate following chronic in utero exposure. Pediatr Pharmacol. 1983;3:1-5.
135. Meut C, Bavoux F, Cynober E, LeBrun F. Necrotizing en-terocolitis in a newborn: maternal psychotropic drugs suspected [letter]. Can J Psychiatry. 1994;39:127.
136. Hill RM, Desmond MM, Kay JL. Extrapyramidal dysfunction in an infant of a schizophrenic mother. J Pediatr. 1966;69:589-595.
137. O'Connor M, Johnson GH, James DI. Intrauterine effects of phenotiazines. Med J Aust. 1981;1:416-417.
138. Tamer A, McKey R, Arias D, Worley L, Foggl BJ. Pheno-thiazine-induced extrapyramidal dysfunction in the neonate. J Pediatr. 1969;75:479-480.
139. Falterman CG, Richardson CJ. Small left colon syndrome associated with maternal ingestion of psychotropic drugs. J Pediatr. 1880;97:308-310.
140. Farag RA, Ananth J. Thanatrophic dwarfism associated with prochlorperazine administration. N Y State J Med. 1978;78:279-282.
141. Mellin GW. Report of prochlorperazine utilization during pregnancy from Fetal Life Study Data Bank [abstract]. Teratology. 1975;11:28A.
142. Rafla N. Limb deformities associated with prochlorperazine [letter]. Am J Obstet Gynecol. 1987;156:1557.
143. Freeman R. Limb deformities: possible association with drugs [letter]. Med J Aust. 1972;3:606-607.
144. Ho CK, Kaufman RL, McAlister WH. Congenital malformations. Cleft palate, congenital hearth disease, absent tibiae, and polydactyly. Am J Dis Child. 1975;129: 714-715.
145. Moriarty AJ, Nance MR. Trifluoperazine and pregnancy [letter]. Can Med Assoc J. 1963;88:375-376
146. Canadian Department of National Health and Welfare, Food and Drug Directorate. Letter of notification to Canadian physicians. 1962. Ottawa, ON.
147. Hall G. A case of phocomelia of the upper limbs [letter]. Med J Aust. 1963;1:449-450.
148. Corner BD. Congenital malformations. Clinical considerations. Med J Southwest. 1962;77:46-52.
149. Vince DJ. Congenital malformations following phenothia-zine administration during pregnancy [letter]. Can Med Assoc J. 1969;100:223.
150. Wheatley D. Drugs and embryo [letter]. Br Med J. 1964;1:631.
151. Schrire I. Trifluoperazine and foetal abnormalities [letter]. Lancet. 1963;1:174.
152. King JT, Barry MC, Neary ER. Perinatal findings in women treated during pregnancy with oral fluphenazine. J New Drugs. 1963;3:21-25.
153. Clearly MF. Fluphenazine decanoate during pregnancy. Am J Psychiatry. 1977;134:815-816.
154. Brougher JC. The treatment of emotional disorders in obstetrics and gynecology with thioridazine. Q Rev Surg Obstet Gynecol. 1960;3:44-47
155. New Zealand Committee on Drug Reactions. Fourth Annual Report. N Z Med J. 1969;70:118-122.
156. Puhó EH, Szunyogh M, Métneki J, Ceizel AE. Drug treatment during pregnancy and isolated orofacial clefts in Hungary. Cleft Palate Craniofac J. 2007;44:194-202.
157. Idänpään-Heikkilä J, Saxen L. Possible teratogenicity of imipramine/chloropyramine. Lancet. 1973;8:282-284.
158. Iqbal MM, Aneja A, Rahman A, et al. Evidence-based pharmacology: the potential risks of commonly prescribed anti-psychotics during pregnancy and lactation. Psychiatry. 2005;2:36-44.
159. Menon SJ. Psychotropic medication during pregnancy and lactation. Arch Gynecol Obstet. 2008;277:1-13.
160. Jain AE, Lacy T. Psychotropic drugs in pregnancy and lactation. J Psychiatr Pract. 2005;11:177-191.
161. Howard L, Webb R, Abel K. Safety of antipsychotic drugs for pregnant and breastfeeding women with non-affective psychosis. Br Med J. 2004;329:933-934.
162. Mental Health Determinants and Populations Department of Mental Health and Substance Dependence. World Health Organization Geneva, 2000. Women's Mental Health: an evidence based review. http://www.WHO-MSD-00.1.pdf. Accessed June 23, 2007.
163. Paton C. Prescribing in pregnancy. Br J Psychiatry. 2008;192:321-322.
164. Narrow WE, First MB, Paul J, Sirovatka PJ, Regier DA. Age and gender Considerations in Psychiatric Diagnosis. A Research Agenda for DSM-V. Arlington, Va: American Psychiatric Pub; 2007.
165. Mastroianni AC, Faden R, Federman S. Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Studies. Washington, DC: Institute of Medicine, National Academy Press; 1994.
166. Pinkofsky HB, Fitzgerald MJ, Reeves RR. Psychotropic treatment during pregnancy [letter]. Am J Psychiatry. 1997;154:718-719.
167. Iqbal MM, Rahman A, Husain Z, Mahmud SZ, Ryan WG, Feldman JM. Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry. 2003;15:33-41.
168. Edward IR, Biriell C. Harmonization in pharmacovigilance. Drug Saf. 1994;10:93-102.
169. Allison DB, Mentore JL, Moonseong H, et al. Antipsy-chotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696.
170. Gentile S. Long term atypical antipsychotics treatment and risk of weight gain. A literature analysis. Drug Saf. 2006;29:303-319.
171. Waller DK, Shaw GM, Rasmussen AS, et al. Prepregnancy obesity as a risk factor for structural birth defects. Arch Pediatr Adolesc Med. 2007;161:745-750.
172. Davson SI. Long-term risk of malignant neoplasm associated with gestational glucose intolerance. Cancer. 2004;100:149-155.
173. Newham JJ, Thomas SH, MacRitchie K, McElhatton P, McAllister-Williams RH. Birth weight of infants after maternal exposure to typical and atypical antipsychotics: prospective comparison study. Br J Psychiatry. 2008;192:333-337.
174. Ahlsson FS, Diderholm B, Ewald U, Gustafson J. Lipolysis and insulin sensitivity at birth in infants who are large for gestational age. Pediatrics. 2007;120:958-965.
175. Nelson MM, Forfar JO. Associations between drugs administered during pregnancy and congenital abnormalities of the fetus. Br Med J. 1971;3:523-527.
176. Perez-Iglesias R, Crespo-Facorro B, Martinez-Garcia O, et al. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-näive population. Schizophr Res. 2008;99:3-22.
177. Gentile S. Schizoaffective disorder in women with childbear-ing potential. In: Murray WH, ed. Schizoaffective Disorders. New Researches. New York, NY187-220.
178. Gentile S. Managing suicidal risk in pregnant schizoaffective women. In: Murray WH, ed. Schizoaffective Disorder: New Research. 2nd ed In press.
179. Ladavac AS, Dubin WR, Ning A, Stuckerman PA. Emergency management of agitation in pregnancy. Gen Hosp Psychiatry. 2007;29:39-41.
180. Schneid-Kofman N, Sheier E, Levy A. Psychiatric illness and adverse pregnancy outcome. Int J Gynecol Obstet. 2008;101:53-56.
181. Schneid-Kofman N, Sheiner E, Levy A. Psychiatric illness and adverse pregnancy outcome. Int J Gynaecol Obstet. 2008;101:53-56.
182. Jablensky AV, Morgan V, Zubrick SR, Bower C, Yellachich LA. Pregnancy, delivery, and neonatal complications in a population cohort of women with schizophrenia and major affective disorders. Am J Psychiatry. 2005;162:79-91.
183. Niemi LT, Suvisaari JM, Haukka JK, Lönnquist JK. Childhood growth and future development pf psychotic disorder among Helsinki high-risk children. Schizophr Res. 2005;76:105-112.
184. Riordan DV, Selvaraj S, Stark C, Gilbert JS. Perinatal circumstances and risk of offspring suicide. Br J Psychiatry. 2006;189:502-507.
185. Rieder RO, Rosenthal D, Wender D, Blumenthal H. The offspring of schizophrenia. Fetal and neonatal deaths. Arch Gen Psychiatry. 1975;32:200-211.
186. Nilsson E, Lichtenstein P, Cnattingius S, Murray RM, Hult-man CM. Women with schizophrenia: pregnancy outcome and infant death among their offspring. Schizophr Res. 2002;58:221-229.
187. Bain M, Juszczak E, McInney K, Kendell RE. Obstetric complications and affective psychosis. Two case-control studies based on structured obstetric records. Br J Psychiatry. 2000;176:523-526. (Pubitemid 30353651)
188. Ellman LM, Huttunen M, Lönqvist J, Cannon D. The effects of genetic liability for schizophrenia and maternal smoking during pregnancy on obstetric complications. Schizophr Res. 2007;93:229-236.
189. Miller LJ. Psychotic denial of pregnancy: phenomenology and clinical management. Hosp Community Psychiatry. 1990;41:1233-1237.
190. Henin A, Biederman J, Mick E, et al. Psychopathology in the offsprings of parents with bipolar disorder: a controlled study. Biol Psychiatry. 2005;58:554-561.
191. Klimes-Dougan B, Ronsaville D, Wiggs EA, Martinez PE. Neuropsychological functioning in adolescent children of mothers with a history of bipolar or major depressive disorders. Biol Psychiatry. 2006;60:957-965.
192. Wais M, Reichart CG, Hillegers MHJ. Prediction of change in level of problem behavior among children of bipolar parents. Acta Psychiatr Scand. 2006;113:23-30.
193. Reichart CG, van der Ende J, Wals M, et al. Social functioning of bipolar offsprings. J Affect Disord. 2007;98:207-213.
194. Patton SW, Misri S, Corral MR, Perry KF, Kuan AJ. Anti-psychotic medication during pregnancy and lactation in women with schizophrenia: evaluating the risk. Can J Psychiatry. 2002;47:959-965.
195. Jain AE, Lacy T. Psychotropic drugs in pregnancy and lactation. J Psychiatr Pract. 2005;11:177-191.
196. Pinkofsky HB. Effects of antipsychotics on the unborn child: what is known and how should this influence prescribing? Paediatr Drugs. 2000;2:83-90.
197. Platt JE, Friedhoff AJ, Broman SH, Bond RN, Laska E, Lin SP. Effects of prenatal exposure to neuroleptic drugs on children's growth. Neuropsychopharm. 1988;1:205-212.
198. Peindl KS, Masand P, Mannelli P, Narasimhan M, Patkar A. Polypharmacy in pregnant women with major psychiatric illness: a pilot study. J Psychiatr Pract. 2007;13: 385-392.
199. Seeman MV. Schizophrenia and motherhood. In: Gopfert M, Webster J, Seeman MV, eds. Parental Psychiatric Disorder. 2nd ed. Cambridge, Mass: Cambrige University Press; 2004.
200. Howard LM, Kumar R, Thornicroft G. Psychosocial characteristics and needs of mothers with psychotic disorders. Br J Psychiatry. 2001;178:427-432.
201. Howard LM, Goss C, Leese M, Appleby L, Thornicroft G. The psychosocial outcome of pregnancy with psychotic disorders. Schizophr Res. 2004;71:49-90.
202. Heinonen OP, Sloane D, Shapiro S. Birth Defects and Drugs in Pregnancy. Littleton, Mass: PSG Publishing; 1977.
203. Hill LM, Breckle R, Gehrking WC. The prenatal detection of congenital malformations by ultrasonography. Mayo Clin Proc. 1983;58:805-826
204. The American Psychiatric Association. Principle of informed consent in psychiatry. Resource document. archi-ve.psych.org/edu/other-res/lib-archives/ archives/199601.pdf. Accessed June 22, 2008.
205. Royal Pharmaceutical Society.Professional Guidance. http://www.pharmj. com/Editorial/20070120/society/p82professio-nalguidance.htlm. Accessed February 2, 2008.
206. Appelbaum PS, Grisso T. The MacArthur Treatment Competence Study: I, mental illness and competence to consent to treatment. Law Hum Behav. 2005;19:105-126
207. Gentile S. More than half of women with a history of psychosis have a psychiatric episode in the first year after childbirth [commentary]. Evid Based Ment Health. 2005;32:33.
208. Gentile S. Managing the suicidal risk in pregnant women with severe and persistent psychiatric disorder. Focus on antisuicidal drugs and somatic interventions. Curr Psychiatry Rev. In press.
209. Nishizawa O, Sakumoto K, Hiramatsu KI, Kondo T. Effectiveness of comprehensive supports for schizophrenic women durino pregnancy and puerperium. Preliminary study. Psychiatr Clin Neurosci. 2007;61: 665-671